<DOC>
	<DOCNO>NCT01615991</DOCNO>
	<brief_summary>Radiation synovectomy intra-articular injection beta-emitting radionuclides consider reliable easy-to-perform therapy without harmful side-effects treatment inflammatory joint disease many country . The goal study demonstrate Yttrium-90 citrate colloid Rhenium-186 sulfide synovectomy appropriate therapeutic intervention patient persistent active synovitis joint ( characterize pain , tenderness , effusion ) resistant systemic therapy intra-articular corticosteroid injection . The primary objective ass safety intra-articular administration Yttrium-90 citrate colloid Rhenium-186 sulfide . The secondary objective ass efficacy synovitis .</brief_summary>
	<brief_title>Multicentre Canadian Study Measure Safety Efficacy Radiosynoviorthesis</brief_title>
	<detailed_description />
	<criteria>There age limit RSO Patient refer medical joint specialist ( orthopedist , rheumatologist internal medicine absence local joint specialist ) Patient refractory inflammatory articular disease : Failure medical therapy 6 month Clinical sign active mono oligo synovitis Joint Xray , echo MR show minimal cartilage bone destruction Pain limit normal activity require significant analgesic medication Prior RSO within last 3 month joint Collapse articular plateau intraarticular fracture Surgery arthroscopy within last 6 week Painful prosthesis Joint infection , local skin infection , bacteremia Joint puncture within last 2 week ( increase risk soft tissue necrosis along needle track ) Pregnancy breast feed Synovial cyst rupture Massive hemarthrosis Generalized synovitis define 5 uncontrolled joint clinical examination 3 phase bone scan Surgical synovectomy within 6months Cancer bone metastases Hypersensitivity , allergies contraindication use radiopharmaceutical agent Participation ongoing clinical trial underlie inflammatory condition</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>